
At the 20th Annual Chemotherapy Foundation Symposium in New York, N.Y., this past November there were numerous presentations about advances in chemotherapy clinical trials that used triplets — combinations of three chemotherapy agents as opposed to more conventional single or double agent therapy. BenchMarks summarizes several presentations that revolve around two newer classes of drugs, called taxanes and platinums, which make up many of the new triplets. BenchMarks also talked to Elise Kohn, M.D., principal investigator, Laboratory of Pathology, National Cancer Institute, to get her perspective on clinical trial design and drug choice.